CohBar, Inc. to Hold 2017 Annual Shareholder Meeting and Investor Update June 15, 2017
MENLO PARK, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) (TSX-V:COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, is hosting its Annual Shareholder Meeting on June 15, 2017.
Details for the Annual Shareholder Meeting:
Date: June 15, 2017
Time: 10:30 a.m. (Pacific Time)
Live Webcast: www.virtualshareholdermeeting.com/COB17
Following the Annual Shareholder Meeting, CohBar will host a conference call and WebEx slide presentation to provide a corporate update for investors.
Details for the Investor Call and Slide Presentation:
Date: June 15, 2017
Time: 2:00 p.m. (Pacific Time)
Audio, Dial-in U.S. and Canada: (877) 723-9519
Audio, Dial-in International: (719) 325-4898
Audio, Conference ID: 9811208
Slide Presentation - www.webex.com, click on the ‘Join’ button and enter meeting number 194 569 017
For individuals participating in the Investor Call and Slide Presentation, we request you please call into the audio and log into WebEx approximately 5-10 minutes before the start of the presentation so that we can begin promptly.
CohBar (OTCQX:CWBR) (TSX-V:COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease (NASH), type 2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 65 biologically active mitochondrial peptides.
For additional company information, please visit www.cohbar.com.
Investor and Media Contact: Anna Schram CohBar, Inc. (650) 446-7888 ext. 114 firstname.lastname@example.org
Released June 1, 2017